Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity

被引:12
作者
Dillon, Roslyn [1 ]
Greig, Michael J. [1 ]
Bhat, B. Ganesh [1 ]
机构
[1] Pfizer Global Res, La Jolla Labs, San Diego, CA 92121 USA
关键词
stearoyl-CoA desaturase; oleic acid; stearic acid; LCMS; sterculic acid; mass spectrometry;
D O I
10.1016/j.aca.2008.05.012
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Stearoyl-CoA desaturase 1 (SCD1) is an enzyme that catalyzes the rate-limiting step in de novo synthesis of monounsaturated fatty acids-mainly oleate and palmitoleate from stearoyl-CoA and palmitoyl-Co A, respectively. These products are the most abundant monounsaturated fatty acids in membrane phospholipids, triglycerides, cholesterol esters. Reports on mice with a targeted disruption of SCD1 gene (SCD1-/-) exhibit improved glucose tolerance and insulin sensitivity compared to wild-type suggesting SCD1 could be a therapeutic target for diabetes and related metabolic diseases. Measurement of SCD1 activity is technically challenging and traditional cell-based SCD1 assay procedure is labor intensive with low throughput. We describe here a novel medium-throughput LC/MS cell-based assay for determining cellular SCD1 activity, facilitating screening of potential SCD1 inhibitor compounds. Confluent HepG2 cells were grown in 24-well plates and incubated with vehicle or an inhibitor followed by incubation with deuterium labeled saturated fatty acid substrates. Total cell lipids were extracted and the conversion of stearate to oleate was measured by liquid chromatography-mass spectrometry. Sterculate, a known inhibitor of SCD1, inhibited the enzyme activity in a dose dependent manner in this assay with a calculated EC50 of 247 nM, The medium-throughput method described here is an important step towards identifying an inhibitor of SCD1 to treat diabetes and related metabolic diseases. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 23 条
[1]   Identification and characterization of a novel gene disrupted by a pericentric inversion inv(4)(p13.1q21.1) in a family with cleft lip [J].
Beiraghi, S ;
Zhou, M ;
Talmadge, CB ;
Went-Sumegi, N ;
Davis, JR ;
Huang, DL ;
Saal, H ;
Seemayer, TA ;
Sumegi, J .
GENE, 2003, 309 (01) :11-21
[2]   Regulation of stearoyl-CoA desaturase activity by the trans-10,cis-12 isomer of conjugated linoleic acid in HepG2 cells [J].
Choi, YJ ;
Park, Y ;
Pariza, MW ;
Ntanbi, JM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 284 (03) :689-693
[3]   Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation [J].
Chu, Kiki ;
Miyazaki, Makoto ;
Man, Weng Chi ;
Ntambi, James M. .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (18) :6786-6798
[4]   Stearoyl-CoA desaturase as a new drug target for obesity treatment [J].
Dobrzyn, A ;
Ntambi, JM .
OBESITY REVIEWS, 2005, 6 (02) :169-174
[5]   The role of stearoyl-CoA desaturase in body weight regulation [J].
Dobrzyn, A ;
Ntambi, JM .
TRENDS IN CARDIOVASCULAR MEDICINE, 2004, 14 (02) :77-81
[6]  
DOBRZYN A, 2005, AM J PHYSIOL-ENDOC M, V288, pES99
[7]  
Gomez FE, 2003, BIOCHEM BIOPH RES CO, V300, P316
[8]   Stearoyl-CoA desaturase-2 gene expression is required for lipid synthesis during early skin and liver development [J].
Miyazaki, M ;
Dobrzyn, A ;
Elias, PM ;
Ntambi, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (35) :12501-12506
[9]   Oleoyl-CoA is the major de novo product of stearoyl-CoA desaturase 1 gene isoform and substrate for the biosynthesis of the Harderian gland 1-alkyl-2,3-diacylglycerol [J].
Miyazaki, M ;
Kim, HJ ;
Man, WC ;
Ntambi, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :39455-39461
[10]   Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid [J].
Miyazaki, M ;
Man, WC ;
Ntambi, JM .
JOURNAL OF NUTRITION, 2001, 131 (09) :2260-2268